Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 131970, 7 pages
http://dx.doi.org/10.1155/2015/131970
Clinical Study

Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma

1Private Office, Vienna, Austria
2Alcon Laboratories, Inc., Fort Worth, TX 76134, USA
3Hospital Municipal de Badalona, 08911 Barcelona, Spain

Received 12 June 2015; Accepted 19 August 2015

Academic Editor: Gianluca Manni

Copyright © 2015 Anton Hommer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Peters, B. Bengtsson, and A. Heijl, “Factors associated with lifetime risk of open-angle glaucoma blindness,” Acta Ophthalmologica, vol. 92, no. 5, pp. 421–425, 2014. View at Publisher · View at Google Scholar
  2. C. A. B. Webers, H. J. M. Beckers, R. M. M. A. Nuijts, and J. S. A. G. Schouten, “Pharmacological management of primary open-angle glaucoma: second-line options and beyond,” Drugs and Aging, vol. 25, no. 9, pp. 729–759, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. W. C. Stewart, A. E. Kolker, E. D. Sharpe et al., “Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma,” European Journal of Ophthalmology, vol. 18, no. 5, pp. 765–770, 2008. View at Google Scholar · View at Scopus
  4. M. A. Kass, D. K. Heuer, E. J. Higginbotham et al., “The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma,” Archives of Ophthalmology, vol. 120, no. 6, pp. 701–713, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. P. N. Schacknow and J. R. Samples, “Medications used to treat glaucoma,” in The Glaucoma Book, P. N. Schacknow and J. R. Samples, Eds., vol. 4, pp. 583–628, Springer, New York, NY, USA, 2010. View at Publisher · View at Google Scholar
  6. F. Djafari, M. R. Lesk, P. J. Harasymowycz, D. Desjardins, and J. Lachaine, “Determinants of adherence to glaucoma medical therapy in a long-term patient population,” Journal of Glaucoma, vol. 18, no. 3, pp. 238–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. L. Robin, G. D. Novack, D. W. Covert, R. S. Crockett, and T. S. Marcic, “Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use,” American Journal of Ophthalmology, vol. 144, no. 4, pp. 533–540, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. European Glaucoma Society, Terminology and Guidelines for Glaucoma, European Glaucoma Society, 2014, http://www.eugs.org/eng/EGS_guidelines.asp.
  9. National Institute of Clinical Excellence, Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension, 2014, http://guidance.nice.org.uk/CG85/Guidance/pdf/English.
  10. American Academy of Ophthalmology Glaucoma Panel, Preferred Practice Pattern Guidelines. Primary Open-Angle Glaucoma, American Academy of Ophthalmology, San Francisco, Calif, USA, 2010.
  11. A. G. P. Konstas, G. Holló, A.-B. Haidich et al., “Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy,” Journal of Ocular Pharmacology and Therapeutics, vol. 29, no. 7, pp. 652–657, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Lanzl and T. Raber, “Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice,” Clinical Ophthalmology, vol. 5, no. 1, pp. 291–298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. B. C. Chauhan, F. S. Mikelberg, P. H. Artes et al., “Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change,” Archives of Ophthalmology, vol. 128, no. 10, pp. 1249–1255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. C. Leske, A. Heijl, M. Hussein, B. Bengtsson, L. Hyman, and E. Komaroff, “Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial,” Archives of Ophthalmology, vol. 121, no. 1, pp. 48–56, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Goldberg, J. G. Crowston, M. C. Jasek, J. A. Stewart, and W. C. Stewart, “Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy,” Journal of Glaucoma, vol. 21, no. 1, pp. 55–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Holló and P. Kóthy, “Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma,” Current Medical Research and Opinion, vol. 24, no. 6, pp. 1755–1761, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. G. P. Konstas, D. Mikropoulos, A. T. Dimopoulos, G. Moumtzis, L. A. Nelson, and W. C. Stewart, “Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy,” British Journal of Ophthalmology, vol. 92, no. 11, pp. 1498–1502, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Akman, A. Cetinkaya, Y. A. Akova, and A. Ertan, “Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination,” Eye, vol. 19, no. 2, pp. 145–151, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. AZARGA, (Brinzolamide 1%/Timolol 0.5% Fixed Combination). Full Prescribing Information, Alcon Laboratories, Surrey, UK, 2013.
  20. C. L. Alexander, S. J. Miller, and S. R. Abel, “Prostaglandin analog treatment of glaucoma and ocular hypertension,” Annals of Pharmacotherapy, vol. 36, no. 3, pp. 504–511, 2002. View at Publisher · View at Google Scholar · View at Scopus